Advertisement
Screener

NeoGenomics, Inc. (NEO) Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price

2.9 / 5 stars · 42/72 Roast Me

NeoGenomics, Inc. Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price

NeoGenomics, Inc. (NEO) had Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price of $27.53 per share as of 2022-12-31, per its 10-K filed 2023-02-24.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 · last filed 2023-02-24

  • 2022-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $27.53.
  • 2021-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $15.29.
  • 2020-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $9.53.
  • 2018-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $7.48; Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price as first filed $6.42.
Period endShare-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise PriceShare-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price as first filed
2022-12-31$27.53
10-K · filed 2023-02-24
2021-12-31$15.29
10-K · filed 2022-02-25
2020-12-31$9.53
10-K · filed 2021-02-25
2018-12-31$7.48
10-K · filed 2020-02-28
$6.42
10-K · filed 2019-02-26
2017-12-31$5.50
10-K · filed 2018-03-13
2014-12-31$1.27
10-K · filed 2015-03-03
2013-12-31$0.89
10-K · filed 2014-02-24
2012-12-31$0.79
10-K · filed 2013-02-21

Similar stocks

Stock NameCountryMarket CapPE Ratio
20/20 Biolabs, Inc. (AIDX)United States$0.005B